colorectal cancer. Neoplasms,Digestive organs
Conditions
Interventions
Intervention 1: Daily supplementation of one 100 mg capsule with food (starting from a week before chemotherapy until the end of second chemotherapy cycle ( a total of 7 weeks). Intervention 2: Daily
Placebo
Daily supplementation of one 100 mg capsule with food (starting from a week before chemotherapy until the end of second chemotherapy cycle ( a total of 7 weeks)
Daily supplementation of one placebo capsule with food (starting form a week before chemotherapy until the end of second chemotherapy cycle ( a total of 7 weeks)
Sponsors
Nutrition Research Center,Tabriz University of Medical
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with colorectal cancer in stage II and III; Life expectancy of more than 3 month; Ability to walk and perform personal tasks; menopause(women) Exclusion criteria: history of chemotherapy in recent 4 weeks; clinical evidence of other metastatic disease, renal and liver disease; diabetes mellitus; thyroid disorders; consumption of vitamin or mineral supplements; under weight(BMI<18.5)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of Matrix Metalloproteinase-7 , 9 (MMP-7,9). Timepoint: Before and after the intervention (7 weeks). Method of measurement: ElISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI. Timepoint: Before and after intervention (7 weeks). Method of measurement: scale with stadiometer.;Interleukin 8. Timepoint: Before and after intervention (7 weeks). Method of measurement: ELISA.;Chemotherapy related Eating issues. Timepoint: Before and after intervention (7 weeks). Method of measurement: questionnaire.;Dietary intake of patients. Timepoint: Before and after intervention (7 weeks). Method of measurement: 24-h food Recall.;MDA and Total antioxidant capacity(TAC). Timepoint: Before and after intervention (7 weeks). Method of measurement: Elisa kit - fluorimetry.;CEA, CA19-9 and thymidine kinase 1. Timepoint: Before and after intervention (7 weeks). Method of measurement: Elisa kit.;Quality of life. Timepoint: Before and after intervention (7 weeks). Method of measurement: Quality of life questionnaire (EORTC QLQ-CR29).;Nutritional status. Timepoint: Before and after intervention (7 weeks). Method of measurement: PG-SGA questionnaire.;TYMS ? MTHFR genotype. Timepoint: Before intervention. Method of measurement: PCR-RFLP. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed